MedTrace Logo

Autologous Adipose Derived Stem Cell Therapy for Intervertebral Disc Degeneration

NCT02338271 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-01-14

No results posted yet for this study

Summary

1. Subject: 10 patients

: Chronic low back pain patients with lumbar intervertebral disc degeneration
2. Investigational Product

: Autologous adipose derived mesenchymal stem cells plus hyaluronic acid derivatives (Tissuefill)
3. Time frame

* 1 year

Conditions

  • Low Back Pain

Interventions

OTHER

autologous adipose derived mesenchymal stem cell

autologous adipose derived mesenchymal stem cell (2 x 10\^7 cells/mL /vial or 4 x 10\^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe

Sponsors & Collaborators

  • CHA University

    collaborator OTHER

  • Inbo Han

    lead OTHER

Principal Investigators

  • Inbo Han, MD, PhD · CHA Bundang Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02338271 on ClinicalTrials.gov